Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows
New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.
Read original article on The Medical News →Related news
-
New fluorescent paper strips make vitamin B12 testing simpler
United Kingdom
-
Robotic assisted hip and knee replacements shows no clear benefit over conventional methods
United Kingdom
-
Before the first bite: A missing gut protein may set the stage for peanut allergy
United Kingdom
-
Discovery explains how immune cells target DNA mutations to improve antibodies
United Kingdom
-
Gut bacterial metabolite worsens brain damage after stroke, study finds
United Kingdom
-
New framework maps depression symptoms to unique brain circuits
United Kingdom
-
Sleep hours miss part of story: Young adults lose sleep quality, not hours, amid heat, noise and light
United Kingdom
-
New recommendations for serrated polyposis syndrome
United Kingdom